These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31396799)

  • 1. Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes.
    German C; Pilvankar M; Przekwas A
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):513-529. PubMed ID: 31396799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBPK-PD model for predicting morphine pharmacokinetics, CNS effects and naloxone antagonism in humans.
    Mu RJ; Liu TL; Liu XD; Liu L
    Acta Pharmacol Sin; 2024 Aug; 45(8):1752-1764. PubMed ID: 38570601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Practical problems associated with long-term opioid therapy].
    Bell RF
    Tidsskr Nor Laegeforen; 1997 May; 117(12):1786-7. PubMed ID: 9213988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of Opioid-Induced Ventilatory Depression Using Low-Dose Naloxone (0.04 mg): a Case Series.
    Kim HK; Nelson LS
    J Med Toxicol; 2016 Mar; 12(1):107-10. PubMed ID: 26289651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal?
    Holzer P
    Curr Pharm Des; 2012; 18(37):6010-20. PubMed ID: 22747544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally.
    Wong A; Macleod D; Robinson J; Koutsogiannis Z; Graudins A; Greene SL
    Clin Toxicol (Phila); 2015; 53(8):815-8. PubMed ID: 26109423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral morphine overdose in a cancer patient antagonized by prolonged naloxone infusion.
    Upadhyay S; Jain R; Chauhan H; Gupta D; Mishra S; Bhatnagar S
    Am J Hosp Palliat Care; 2008; 25(5):401-5. PubMed ID: 18539764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The attractiveness of opposites: agonists and antagonists.
    O'Brien T
    J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):67-9. PubMed ID: 25643224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative analgesia after radical prostatectomy with high-dose intrathecal morphine and intravenous naloxone: a retrospective review.
    Rebel A; Sloan P; Andrykowski M
    J Opioid Manag; 2009; 5(6):331-9. PubMed ID: 20073407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing methods of naloxone administration: A narrative review.
    Fellows SE; Coppola AJ; Gandhi MA
    J Opioid Manag; 2017; 13(4):253-260. PubMed ID: 28953317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation.
    Mueller-Lissner S
    Adv Ther; 2010 Sep; 27(9):581-90. PubMed ID: 20714946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
    Sekar V; Tomaka F; Lefebvre E; De Pauw M; Vangeneugden T; van den Brink W; Hoetelmans R
    J Clin Pharmacol; 2011 Feb; 51(2):271-8. PubMed ID: 20421512
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.
    Webster LR; Johnson FK; Stauffer J; Setnik B; Ciric S
    Drugs R D; 2011 Sep; 11(3):259-75. PubMed ID: 21902287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A morphine/naltrexone combination (Embeda) for pain.
    Med Lett Drugs Ther; 2010 Mar; 52(1334):22-3. PubMed ID: 20336033
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical Pharmacokinetics and Pharmacodynamics of Naloxone.
    Saari TI; Strang J; Dale O
    Clin Pharmacokinet; 2024 Apr; 63(4):397-422. PubMed ID: 38485851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the appropriateness of naloxone administration to patients receiving long-term opioid therapy.
    Facey C; Brooks D; Boland JW
    Hosp Pract (1995); 2016; 44(2):86-91. PubMed ID: 26837434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal.
    Mundin G; McDonald R; Smith K; Harris S; Strang J
    Addiction; 2017 Sep; 112(9):1647-1652. PubMed ID: 28430384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
    Setnik B; Roland CL; Goli V; Sommerville K; Webster L
    J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.